Skip to main content

March 2016, Vol 9, Seventh Annual Payers' Guide

FDA Approvals, Payers' Guide
Welcome to the Seventh Annual Payers' Guide to New FDA Approvals
Read More
FDA Approvals, Payers' Guide
Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals
Caroline Helwick
Read More
FDA Approvals, Payers' Guide
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
Read More
Page 3 of 5
Results 21 - 30 of 43